Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
Type:
Grant
Filed:
July 28, 2020
Date of Patent:
September 27, 2022
Assignee:
SANOFI
Inventors:
Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).
Type:
Grant
Filed:
October 26, 2021
Date of Patent:
September 20, 2022
Assignees:
Saitama Medical University, Daiichi Sankyo Company, Limited
Abstract: The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants.
Type:
Grant
Filed:
June 16, 2014
Date of Patent:
September 6, 2022
Assignee:
AMGEN INC.
Inventors:
Christopher James Sloey, Jason Ko, Tiansheng Li
Abstract: A vaccine composition for immunizing and/or protecting a mammal against an IL-31 mediated disorder is provided, wherein the composition includes: the combination of a carrier polypeptide and at least one mimotope selected from a feline IL-31 mimotope, a canine IL-31 mimotope, a horse IL-31 mimotope, and a human IL-31 mimotope; and an adjuvant. Such vaccines can be in the form of pharmaceutical compositions useful for treating or protecting mammals such as cats, dogs, horses, or humans against IL-31-mediated disorders.
Type:
Grant
Filed:
March 18, 2019
Date of Patent:
September 6, 2022
Assignee:
Zoetis Services LLC
Inventors:
Gary Francis Bammert, Steven Alan Dunham
Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
Type:
Grant
Filed:
October 1, 2020
Date of Patent:
August 16, 2022
Assignee:
Janssen Biotech, Inc.
Inventors:
Ken Boakye, Alfred Del Vecchio, John Kehoe, Eilyn Lacy, Lynne Murray, Mary Ryan, Sandra Santulli-Marotto, John Wheeler, Brian Whitaker, Alexey Teplyakov
Abstract: Siglec-15 binding molecules are provides. The molecules are typically an antibody or antigen binding fragment thereof that immunospecifically binds to Siglec-15. Siglec-15 ligand-binding molecules are also provided. The molecules are typically Siglec-15 polypeptide or fusion protein. Methods of using the molecules to reduce Siglec-15 mediated immunosuppression in a subject in need thereof are also provided.
Type:
Grant
Filed:
September 21, 2017
Date of Patent:
July 19, 2022
Assignee:
NEXTCURE, INC.
Inventors:
Linda Liu, Benjamin Dallas Flies, Solomon Langermann
Abstract: Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.
Type:
Grant
Filed:
January 14, 2020
Date of Patent:
July 19, 2022
Assignee:
The Scripps Research Institute
Inventors:
Vaughn Smider, Omar A. Bazirgan, Hongyuan Helen Mao, Peter Schultz, Feng Wang, Yong Zhang
Abstract: The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.
Abstract: The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
Abstract: The described invention provides soft tissue grafts, hard tissue grafts, and composite soft/hard tissue grafts and methods of producing such grafts. The grafts comprise a three-dimensional carrier matrix, a growth factor composition comprising an autologous platelet-rich fibrin and a cell culture composition comprising a culture medium, a population of cells suspended in the culture medium, and cells impregnated on or in a surface of osteoconductive particles.
Type:
Grant
Filed:
September 11, 2019
Date of Patent:
June 21, 2022
Assignee:
REJUVABLAST LLC
Inventors:
Nicholas Elian, Sean M. O'Connell, William K. Boss, Jr.
Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
Type:
Grant
Filed:
February 7, 2020
Date of Patent:
June 14, 2022
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Darrin Anthony Lindhout, Raj Haldankar, Hui Tian, Jer-Yuan Hsu
Abstract: The disclosure relates to long acting parathyroid or parathyroid hormone like fusion polypeptides comprising a receptor polypeptide and its use in the treatment of hypoparathyroidism and osteoporosis.
Abstract: The present disclosure relates to antibodies and binding fragments to a Tenascin, in particular the FBG domain of a Tenascin, which are potentially less immunogenic than the parent antibody. The disclosure also relates to compositions comprising the antibody or binding fragment and use of any one of the same for diagnosis, prognosis and/or treatment of disorders such as those associated with chronic inflammation. The disclosure further provides methods of making the antibodies.
Type:
Grant
Filed:
February 10, 2017
Date of Patent:
May 17, 2022
Assignee:
STERLING IP LIMITED
Inventors:
Patrick Hextall, Kim Suzanne Midwood, Eric Culbert
Abstract: The present invention provides an antibody facilitating programmed necrosis of cells. The antibody can cause programmed necrosis of cells in the presence of tumor necrosis factor (TNF). Therefore, an inhibitor for the antibody can be used in the treatment of inflammatory diseases. Further, the present invention provides the application of the antibody facilitating programmed necrosis of cells in the inflammatory disease prognosis.
Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
Abstract: Provided herein are monoclonal antibodies (e.g., human antibodies) binding to human Growth Differentiation Factor 15 protein (hereinafter, sometimes referred to as “GDF15”), and pharmaceutical compositions and methods of treatment comprising the same.
Type:
Grant
Filed:
April 26, 2017
Date of Patent:
April 26, 2022
Assignee:
NOVARTIS AG
Inventors:
Hong Chen, Rajiv Chopra, Seung Wan Hahm, Norio Hamamatsu, Ryan Scott Streeper, Mei Xu
Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).
Type:
Grant
Filed:
August 19, 2019
Date of Patent:
April 26, 2022
Assignees:
Saitama Medical University, Daiichi Sankyo Company, Limited
Abstract: The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.
Type:
Grant
Filed:
April 14, 2017
Date of Patent:
March 22, 2022
Assignee:
OSE IMMUNOTHERAPEUTICS
Inventors:
Nicolas Poirier, Caroline Mary, Bernard Vanhove, Vanessa Gauttier, Virginie Thepenier, Sabrina Pengam
Abstract: A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo.
Type:
Grant
Filed:
May 29, 2018
Date of Patent:
March 22, 2022
Assignee:
NOVAGEN HOLDING CORPORATION
Inventors:
Haitao Wang, Yong Du, Rui Zhang, Jing Xu, Longbin Liu